LGALS3 and aortic valve stenosis: In patients with severe AS undergoing TAVR, elevated galectin-3 levels ≥ 8.71 ng/mL predicted adverse clinical outcomes (all-cause mortality or readmission for worsening HF) only when carbohydrate antigen 125 (CA-125) was additionally elevated [109].